United Therapeutics CEO trust sells 9,500 shares
The pre-arranged plan will continue until exercise of 1,734,410 options or December 31, 2026, whichever occurs first; the options expire March 15, 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt reported that a family trust in which she shared investment power exercised 9,500 stock options at an exercise price of $117.76 per share on October 16, 2026, acquiring 9,500 common shares and selling 9,500 resulting shares in 13 reported sales. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. The reported post-exercise balance was 214,410 stock options.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F18, F19 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 240 | $530.4754 | $127K |
| Sale | Common Stock F1, F4, F2 | 1,024 | $531.5387 | $544K |
| Sale | Common Stock F1, F5, F2 | 2,378 | $532.4628 | $1.27M |
| Sale | Common Stock F1, F6, F2 | 1,818 | $533.3216 | $970K |
| Sale | Common Stock F1, F7, F2 | 640 | $534.4103 | $342K |
| Sale | Common Stock F1, F8, F2 | 535 | $535.6665 | $287K |
| Sale | Common Stock F1, F9, F2 | 865 | $536.657 | $464K |
| Sale | Common Stock F1, F10, F2 | 760 | $537.7381 | $409K |
| Sale | Common Stock F1, F11, F2 | 401 | $538.5509 | $216K |
| Sale | Common Stock F1, F12, F2 | 239 | $539.6002 | $129K |
| Sale | Common Stock F1, F13, F2 | 169 | $541.6201 | $92K |
| Sale | Common Stock F1, F14, F2 | 391 | $542.6735 | $212K |
| Sale | Common Stock F1, F2 | 40 | $543.85 | $22K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F15 | -- | -- | -- |
| holding | Common Stock F16 | -- | -- | -- |
| holding | Common Stock F17 | -- | -- | -- |
Footnotes (19)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $537.22 to $538.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $538.22 to $538.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $539.28 to $539.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $541.26 to $542.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $542.28 to $543.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F15. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F16. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F17. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F18. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F19. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $529.95 to $530.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $530.95 to $531.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $531.96 to $532.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $532.98 to $533.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $534.04 to $534.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $535.22 to $536.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $536.22 to $537.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
pre-arranged 10b5-1 trading plan regulatory
weighted average price financial
investment power regulatory
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the UTHR option exercise price reported for Martine A. Rothblatt?
How long does the UTHR Rule 10b5-1 plan continue?
AI-generated analysis. How Rhea-AI works. Not financial advice.